Richardson PG, Schlag R, Khuageva N, Dimopoulos M, Shpilberg O, Kropff M, Vekemans M-C, Petrucci MT, Rossiev V, Hou J, et al. Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agent. British Journal of Haematology [Internet]. 2011;153(2):212 - 221.